AMST
Amesite Inc.2.3900
-0.0600-2.45%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
10.93MP/E (TTM)
-Basic EPS (TTM)
-0.83Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Amesite's Q2 FY2026 revenue jumped to $108K, up 747% y/y from $12.8K yet flat q/q, with B2B at 78% of the mix versus prior customer concentration risks. Operating loss narrowed to $745K from $1.1M y/y, fueled by 28% cuts across G&A, tech, and sales while staff scaled back. Cash burned $1.0M in ops (FCF not disclosed in the 10-Q), leaving $1.3M total including $100K restricted. Losses match across periods; EPS aligns with 4.57M shares, anti-dilutive. Nasdaq equity compliance hangs in the balance.
8-K
69% QoQ revenue jump
Amesite released a shareholder update on October 30, 2025, touting 69% QoQ revenue growth in Q2 2026 while slashing operating expenses. Customer reviews praise NurseMagic's 95% documentation time cuts in post-acute care. Revenue doubled prior quarter too. Plans target AI-powered EMR launch by Q2 2026.
8-K
Nasdaq equity deficiency notice
Amesite Inc. received a Nasdaq deficiency notice on October 28, 2025, for failing to meet the $2.5M stockholders' equity rule or alternative standards like $35M market value or $500K net income. Shares continue trading uninterrupted under AMST. It plans to submit a compliance plan within 45 days. No assurance of success.
10-Q
Q1 FY2026 results
Amesite ramped revenue to $94k in Q1 FY2026 ended September 30, 2025, up sharply from $11k y/y, with B2B at 74% driving the surge while B2C added 26%. Operating loss narrowed to $662k from $927k y/y as G&A, tech, and sales expenses fell across the board. Net loss of $642k reflects steady $20k interest income; stock-based comp at $72k widened the gap from operating loss. Cash burned $416k on operations, $88k on software capex, leaving $1.8M unrestricted plus $100k restricted. Expenses dropped. Going concern doubts linger.
10-K
FY2025 results
Amesite narrowed FY2025 net loss to $3.6M from $4.4M in FY2024, while revenue dipped to $110K from $167K amid a strategic pivot to NurseMagic™ AI healthcare tools—B2C grabbed 24% of sales, B2B 76%. Costs slashed across G&A (down 15%), tech development (down 36%), and sales/marketing (down 29%), fueled by board resignations and payroll cuts, yet a $91K software impairment hit from ditching higher-ed focus. Q4 momentum built post-HIPAA compliance in April 2025 and Enterprise launch in July, with NurseMagic Teams+ driving adoption. Cash sits at $2.3M after a $3.1M January offering. Substantial doubt lingers on going concern.
AIFF
Firefly Neuroscience, Inc.
1.41-0.06
ALIT
Alight, Inc.
2.06+0.00
ALKT
Alkami Technology, Inc.
22.15+0.37
AMPL
Amplitude, Inc.
11.02+0.27
CRM
Salesforce, Inc.
254.91+0.33
EXFY
Expensify, Inc.
1.56+0.02
NRDY
Nerdy Inc.
1.20-0.07
NTCL
NETCLASS TECHNOLOGY INC
0.73-0.22
TRSO
TRANSUITE.ORG INC.
0.10+0.00
WONDF
Wonderfi Technologies Inc.
0.21+0.00